Open AccessRECOMBINANT ANTIBODIES IN ANTI-VIRAL THERAPY: ACHIEVEMENTS AND PERSPECTIVES
Author(s) -
Alexey S. Oksanich,
Alexandra Nikonova,
В. В. Зверев
Publication year - 2018
Publication title -
žurnal mikrobiologii, èpidemiologii i immunobiologii
Language(s) - English
Resource type - Journals
eISSN - 2686-7613
pISSN - 0372-9311
DOI - 10.36233/0372-9311-2018-6-114-123
Subject(s) - monoclonal antibody , medicine , antibody , virology , recombinant dna , immunology , biology , biochemistry , gene
More than 60 recombinant monoclonal antibodies (mAbs) have been developed for the treatment of various diseases in the last 20 years. About 30 antibody preparations are approved for use in therapy, including large group of drugs against cancer. In addition, mAbs are used in transplantation, for the treatment of cardiovascular, autoimmune and, in rare cases, infectious diseases. Despite the fact that tens millions of people die every year from viral diseases, only one drug based on recombinant antibodies for the prevention of RSV in children is currently allowed. This review focuses on approaches to generate therapeutic mAbs to fight viral infection, examples of mAb therapies for viral infections, and the challenges of developing such therapies.